Infant Formula Fiasco Weighs On Abbott's Q3 Earnings, Still It Raised FY22 EPS Guidance

  • Abbott Laboratories ABT has reported Q3 FY22 adjusted EPS of $1.15, down 17.9% Y/Y, better than the consensus of $0.94.
  • Q3 sales of $10.4 billion decreased 4.7% on a reported basis and increased 1.3% on an organic basis, beating the consensus of $9.64 billion.
  • Q3 sales were negatively impacted by declines in COVID-19 testing-related sales and a manufacturing stoppage of certain infant formula products. 
  • Excluding COVID-19 testing-related sales and the infant formula stoppage, sales were down 0.6% (up 6% organically).
  • Also Read: Abbott Says Recent Recall Of Some Bottles Of Infant Formula Will Not Hamper Supply.
  • Global COVID-19 testing-related sales were $1.67 billion, compared to $1.91 billion a year ago.
  • Worldwide Nutrition sales decreased 14.9% on a reported basis and 10.3% on an organic basis in the third quarter.
  • U.S. Medical Devices sales grew 11.3%, led by double-digit growth in Electrophysiology, Structural Heart, and Diabetes Care.
  • Outlook: Abbott has increased FY22 adjusted EPS guidance to $5.17-$5.23 compared to the earlier guidance of $4.90 and the consensus of $5.05.
  • FY22 guidance assumes COVID-19 testing-related sales of $7.8 billion, which includes sales of $7.3 billion through September 2022 and projected sales of $0.5 billion in Q4.
  • Price Action: ABT shares are down 3.31% at $101.50 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!